title: Is the tolerance to MIP chemotherapy different between English and other European populations?
authors.forename: T
authors.initials: T
authors.lastname: Berghmans
authors.forename: J P
authors.initials: JP
authors.lastname: Sculier
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D017326:Clinical Trials, Phase III as Topic; D003657:Decision Making; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004739:England; D005060:Europe; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy*; D016685:Mitomycin / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D016685:Mitomycin; D016190:Carboplatin; D002945:Cisplatin; D007069:Ifosfamide; D000093542:Gemcitabine